Full text is available at the source.
Cost-effectiveness of intermittent preventive treatment with dihydroartemisinin-piperaquine versus single screening and treatment for the control of malaria in pregnancy in Papua, Indonesia: a provider perspective analysis from a cluster-randomised trial
Cost-effectiveness of preventive malaria treatment versus single screening during pregnancy in Papua, Indonesia from a healthcare provider perspective
AI simplified
Abstract
Intermittent preventive treatment with dihydroartemisinin-piperaquine averted 107.4 disability-adjusted life-years (DALYs) per 1000 women at an incremental cost of $5657 compared to single screening and treatment.
- The average cost-effectiveness ratio was $53 per DALY averted.
- Intermittent preventive treatment is proposed as a promising alternative for reducing malaria in pregnancy.
- The higher cost of intermittent preventive treatment was largely due to the need for monthly administration.
- DALYs were calculated based on outcomes such as fetal loss, neonatal death, low birthweight, maternal anemia, and clinical malaria.
- Cost estimates were derived from observational studies and health facility costing data.
AI simplified